The dip recently to once again below $4 was painful for the longs, but fortunately some of us bought even more. The funding round was coming and some insiders knew more $3.25s would be issued. I certainly hope that is the last time we'll see $3.25s - with just the $5.50 warrants above them.
The stock is impossible to trade a decent large block. Nibbling, even slightly, takes the sellers off the ask. It's been like that since it got back up above $4. Before the dip, you could hit the ask and eventually they'd lower it - getting it down so the $3.25 new warrants didn't look too much like a big give away.
The last two days have been telling. Eight weeks to get through $6 last time -- this week it took about 4k shares to breach the level. And lastly we saw a 40cent uptick in the last minute today on about 12k. The A/D line is pretty impressive.
My big question is how quickly can OCX generate meaningful revenues from international distribution and partnerships while they pursue US reimbursements? It's nice that hardly anyone follow this board b/c it means I'm ahead of the party. But can any one of the five of you reading this board talk about my question above?
I am counting on OCX having at least one announcement lined up with an international partner to be signed and released following the completion of the two outstanding validation trials. So how quickly will partnerships come once they are clear to make and sell?
With that said - I look forward to the day when we have 1000 messages on this board. Then we'll know the word is out. I am stunned by how so few folks are following or even aware of this nifty unique investment opportunity.
Good luck to all longs. We've got a phenomenal management team working for us and I for one am getting excited about how well they are delivering.
Tim
Recent OCX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 11:40:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 10:05:29 AM
- Oncocyte Signs Leading Transplant Centers in US and Germany • GlobeNewswire Inc. • 10/02/2024 10:41:25 PM
- Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 10/02/2024 10:35:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/25/2024 08:09:08 PM
- PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology • GlobeNewswire Inc. • 08/20/2024 01:00:00 PM
- Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study • GlobeNewswire Inc. • 08/12/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 10:37:23 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 10:25:21 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/09/2024 04:15:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:27:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:10:22 PM
- Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Oncocyte Announces August Investor Conferences Participation • GlobeNewswire Inc. • 08/05/2024 08:05:00 PM
- Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:05:21 PM
- MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode • GlobeNewswire Inc. • 07/11/2024 12:00:00 PM
- Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move • GlobeNewswire Inc. • 06/24/2024 04:41:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:10:27 PM
- Oncocyte Appoints Andrea James as Chief Financial Officer • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/04/2024 09:02:47 PM
- Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study • GlobeNewswire Inc. • 06/03/2024 06:13:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:31 PM
- Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine • GlobeNewswire Inc. • 05/30/2024 08:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:24 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM